News About: Pharm. Industry
The poor performance report of top pharmaceutical companies on the fourth quarter… both in sales and profits
It is analyzed performances of the top 4 listed pharmaceutical companies in sales were slowed down.
Declined market shares of the top pharmaceutical companies can be explained byadvances of mid-sized pharmaceutical c...
Handok Teva recorded the lowest price in generics of Baraclude exceeding Hanmi
Generics of the hepatitis type B treatment Baracludes (entecavir), which recorded the most prescription expenses, have competed fiercely to register low prices.
As Hanmi Pharmaceutical volunteered to reduce its drug ...
The Canadian generic pharmaceutical company ‘Pharmascience’ will enter the Korea market
Co-established by the Canadian generic pharmaceutical company, ‘Pharmascience’, and ‘Kolmar Korea’, ‘Pharmascience Korea’ has got its active business operation.
Morris Goodman, president of Pharmascience, held a pres...
The OchangFactorys invested by Celltrion Pharm with KRW 150 billion will run actively soonThe CelltrionPharm’sOchang Factory has begun to manufacture for this year after finishing the legal process.
According to the Celltrion Pharm on the 21st, the Ochang Factory wa...
|
Multinational pharmaceutical companies chases the new target, ‘OTC drugs’
In the past, ‘multinational pharmaceutical companies’ were recognized to focus on manufacturing ETC (Ethical) drugs, like antibiotics, but it seems that the trend is changing lately.
It is observed that they have exp...
Samsung begun to acquire the biosimilar of ‘Enbrel’ in EuropeSamsung has pushed ahead to acquire the European approval of the ‘Enbrel’biosmilar.
Samsung Bioepis announced that the European Medicines Agency (EMA) completed reviewing the a...
|
Hanmi and SK will develop generics of Xarelto
It is observed that the generic of the 2nd generation anticoagulant ‘Xarelto’ is being developed.
It is known that the owner company of ‘Xarelto’, Bayer Korea, acquired an approval for the bioequivalence test plan to...
Sales of Fulcare were drastically increased with KRW 25.2 billion… the ‘synergy’ effect of pharmaceutical distribution partnerships was the reason
As sales of the athlete’s foot and hand treatment ‘Fulcare’ have been tripled, the case have been called as an example a ‘Win-Win’ case between a pharmaceutical company and distribution companies.
Although Fulcare re...
While Pradaxa was suffering, Xarelto was increased by 103%... why it that?
What has happened in the year?
It is known that the prescription expense ranking for the next generation new oral anticoagulant (NOAC) was changed last year. According to the UBIST, a company finding the total of out...
Should a pharmaceutical company cease on manufacturing pharmaceutical products if not profitable? The pharmaceutical industry is in a dilemma.
There are enormous amounts of drugs that experienced significant price drops after the En Bloc Drug Price Reduction in 2012. However, some pharmaceutical products are even getting deficits as they are sold. The produc...
